{"id":1184,"date":"2011-11-25T11:00:00","date_gmt":"2011-11-25T11:00:00","guid":{"rendered":"http:\/\/www.emlitofnote.com\/?p=1184"},"modified":"2016-08-01T08:58:54","modified_gmt":"2016-08-01T15:58:54","slug":"tpa-is-safe-in-prior-stroke-and-diabetics","status":"publish","type":"post","link":"https:\/\/www.emlitofnote.com\/?p=1184","title":{"rendered":"TPA Is &#8220;Safe&#8221; In Prior Stroke and Diabetics"},"content":{"rendered":"<p>Another recent Journal Watch article about TPA &#8211; relaying the manufacturer-sponsored message that TPA can, in fact, be given to the patients who were excluded from ECASS III because of diabetes or prior stroke.<\/p>\n<p>Papers like this are fabulous. &nbsp;I am 100% in agreement with the physiologic premise that timely reperfusion of the ischemic penumbra is beneficial in acute stroke. &nbsp;I am less enthusiastic about using systemic thrombolysis, because it&#8217;s akin to smashing a teacup with a sledgehammer. &nbsp;But, until PCI-like therapy is available\/safe for the brain, it&#8217;s all we have.<\/p>\n<p>I am really tired of endless papers from the TPA literature with authors falling all over themselves to present fundamentally flawed data as definitive evidence. &nbsp;In this paper, the authors take the non-randomized TPA population from the SITS-ISTR &#8211; and compare it to the non-randomized, non-thrombolyzed population from the VISTA registry. &nbsp;Why is this a problem? &nbsp;Because even though the relative differences are large, the absolute differences are small &#8211; and we&#8217;ve already see that what makes the largest absolute difference is&nbsp;<a href=\"https:\/\/www.emlitofnote.com\/2011\/10\/stroke-after-care-is-far-more-important.html\">stroke after-care<\/a>, and that all stroke centers are not created equal. &nbsp;The authors acknowledge this, but then justify their results by stating that their numbers are similar to prior, retrospective, non-randomized comparisons performed on subsets of registry data. &nbsp;It&#8217;s a self-fulfilling prophecy.<\/p>\n<p>They conclude with &#8220;Hence, we find no justification to exclude patients from receiving alteplase for acute ischemic stroke if they have a [prior stroke] and also have [diabetes mellitus]&#8221; &#8211; which is true, unless it bothers you that the mRS 6 (dead) group nearly doubles when TPA is given to the stroke\/diabetes groups. &nbsp;Imagine what the reaction to ECASS III would be if TPA wasn&#8217;t 52% good outcome vs 6.7% death &#8211; and was one of these 29% good outcome vs. 23% death, or 25% good outcome vs. 28% death comparisons from the registry data (totally different baseline severity vs. ECASS III, just throwing the numbers out there for hyperbole).<\/p>\n<p>&#8230;and, the obligatory:<\/p>\n<div>&#8220;Dr. Mishra reports no disclosures. Dr. Ahmed is an employee of SITS International, which received a grant from <b>Boehringer Ingelheim<\/b> for the SITS-MOST\/SITS-ISTR study with alteplase. Dr. Davalos has received speaker or consultancy honoraria from AstraZeneca, <b>Boehringer Ingelheim<\/b>, Lundbeck Inc., ev3, Ferrer, and Talecris Biotherapeutics. Dr. Iversen has served on scientific advisory boards for <b>Boehringer Ingelheim<\/b> and Allergan, Inc.; and has received research support from the Danish National Advanced Science Foundation. Dr. Melo reports no disclosures. Dr. Soinne serves on speakers\u2019 bureaus for and has received speaker honoraria from <b>Boehringer Ingelheim<\/b>, Pfizer Inc, and Siemens; and has served as a consultant for <b>Boehringer Ingelheim<\/b>. Dr. Wahlgren serves as Chairman of the SITS Scientific Committee; has served on scientific advisory boards for <b>Boehringer Ingelheim<\/b> and ThromboGenics NV; has received funding for travel and speaker honoraria from <b>Boehringer Ingelheim<\/b>, Lundbeck Inc., and Ferrer; and serves on the editorial boards of Stroke and Cerebrovascular Diseases. Dr. Lees serves on scientific advisory boards for <b>Boehringer Ingelheim<\/b>, Talecris Biotherapeutics, Lundbeck Inc., Ferrer, and PhotoThera; and has received speaker honoraria from <b>Boehringer Ingelheim<\/b>, Lundbeck Inc., ThromboGenics NV, and Talecris Biotherapeutics.&#8221;<\/div>\n<div><\/div>\n<div>I want to use TPA to treat stroke without reservations, but the literature is broken. &nbsp;Still hoping&nbsp;<a href=\"http:\/\/www.dcn.ed.ac.uk\/ist3\/\">IST-3<\/a>&nbsp;will help define a low-risk population that benefits.<\/div>\n<div><a href=\"http:\/\/www.blogger.com\/\"><\/a><\/div>\n<div><\/div>\n<div>&#8220;Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus&#8221;<\/div>\n<div><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22094479\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22094479<\/a><\/div>\n\n<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?via=emlitofnote\" class=\"twitter-share-button\">Tweet<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Another recent Journal Watch article about TPA &#8211; relaying the manufacturer-sponsored message that TPA can, in fact, be given to the patients who were excluded from ECASS III because of diabetes or prior stroke. Papers like this are fabulous. &nbsp;I am 100% in agreement with the physiologic premise that timely reperfusion of the ischemic penumbra &hellip; <a href=\"https:\/\/www.emlitofnote.com\/?p=1184\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TPA Is &#8220;Safe&#8221; In Prior Stroke and Diabetics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[14,15],"tags":[],"class_list":["post-1184","post","type-post","status-publish","format-standard","hentry","category-neurology","category-stroke"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7KesJ-j6","jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/posts\/1184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1184"}],"version-history":[{"count":1,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/posts\/1184\/revisions"}],"predecessor-version":[{"id":2933,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=\/wp\/v2\/posts\/1184\/revisions\/2933"}],"wp:attachment":[{"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emlitofnote.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}